ArticleEuropean journal of clinical pharmacology2026
Non-steroidal anti-inflammatory drug use in patients with varying severity of coronary artery disease.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unmeasured competing risk of death and NSAID-subtype heterogeneity in the assessment of NSAID use across coronary artery disease severity.European journal of clinical pharmacology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe examined temporal trends in NSAID use among patients referred for evaluation of suspected coronary artery disease (CAD).
methodsWe conducted a drug utilisation study using population-based healthcare data from Western Denmark, covering 3.3 million inhabitants. Three cohorts were categorised based on first-time diagnostic procedure for CAD assessment: coronary computed tomography angiography (CCTA; 2008-2022, n = 91,230), myocardial perfusion imaging (MPI; 2016-2022, n = 17,044), and all invasive coronary angiograms (ICA; 2008-2022, n = 128,327). We calculated the one-year prevalence proportion of NSAID use after the diagnostic procedures, stratified by procedure-defined CAD severity.
resultsNSAID use declined over the study period, regardless of CAD severity in patients undergoing CCTA or ICA (p < 0.001). In 2021, the one-year prevalence of NSAID use was 17% among patients with severe CAD vs. 24% among patients without CAD diagnosed using CCTA (prevalence proportion ratio [PPR] 0.73, 95% confidence interval [CI]: 0.60-0.90). In patients undergoing MPI, 9% of those with severe CAD vs. 15% of those with no CAD used NSAIDs (PPR 0.58, 95% CI: 0.45-0.73). In patients undergoing ICA, 10% of those with severe CAD and 20% of those with no CAD used NSAIDs (PPR 0.53, 95% CI: 0.44-0.62).
conclusionAlthough NSAID use among patients with CAD has decreased and is lower than among patients without CAD, it remains relatively high in those with severe CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.